Brief: Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428
04/08/2026 13:22
BRIEF-Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428 Aug 4 (Reuters) - Fujian Haixi Pharmaceuticals Co Ltd 2637.HK:
U.S. FDA APPROVES IND APPLICATION OF HX9428 FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Further company coverage: 2637.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fujian Haixi Pharmaceuticals
See all newsBrief: Fujian Haixi Pharmaceuticals Says HX9428 Granted Fast Track Designation By U.S. FDA
Fujian Haixi jumps on initial approval of HX9428 for macular degeneration treatment
Brief: Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428
Brief: Fujian Haixi Pharmaceuticals Elects Chen Tingze As Executive Director
Brief: Fujian Haixi Pharmaceuticals Nominates Chen Tingze As Candidate For Executive Director